10-QPeriod: Q2 FY2022

CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2022

Filed August 3, 2022For Securities:CVS

Summary

CVS Health Corporation reported solid financial results for the second quarter and first half of 2022, with total revenues increasing by 11.0% year-over-year for the quarter to $80.6 billion and 11.1% for the first half to $157.5 billion. This growth was driven by strong performance across all segments, particularly in Products and Premiums. Net income attributable to CVS Health increased by 6.0% for the quarter to $2.95 billion and 5.1% for the first half to $5.26 billion. The company also benefited from the divestiture of PayFlex, which contributed a pre-tax gain of $225 million in the second quarter. Despite facing ongoing operational costs and legal settlements, including a significant opioid settlement with the State of Florida, CVS Health demonstrated resilience and continued to return capital to shareholders through share repurchases and dividends. The company's outlook remains focused on integrating its health services offerings and driving cost efficiencies.

Financial Highlights

55 data points
Beta

Revenue

$80.64B

38.9% Gross Margin

Net Income

$3.04B

3.8% Net Margin

EPS (Diluted)

$2.29

Total Assets

$230.28B

Cash & Equivalents

$12.12B

Free Cash Flow

$5.04B

Financial Statements
Beta
Revenue$80.64B
Cost of Revenue$49.29B
Gross Profit$31.35B
Operating Expenses$75.97B
Operating Income$4.67B
Interest Expense$583.00M
Net Income$3.04B
EPS (Basic)$2.31
EPS (Diluted)$2.29
Shares Outstanding (Basic)1.31B
Shares Outstanding (Diluted)1.32B

Key Highlights

  • 1Total revenues increased by 11.0% year-over-year for the quarter to $80.6 billion and 11.1% for the first half to $157.5 billion, driven by growth across all segments.
  • 2Net income attributable to CVS Health grew 6.0% year-over-year for the quarter to $2.95 billion ($2.23 per diluted share) and 5.1% for the first half to $5.26 billion ($3.97 per diluted share).
  • 3The divestiture of PayFlex on June 1, 2022, generated a pre-tax gain of $225 million, contributing positively to operating income in the Health Care Benefits segment.
  • 4Operating income saw a 5.6% increase for the quarter to $4.6 billion, supported by gains and improved segment performance, although partially offset by legal settlements.
  • 5The company repurchased approximately $2.0 billion of its common stock during the first six months of 2022, demonstrating a commitment to returning capital to shareholders.
  • 6Despite a $484 million legal settlement related to opioid claims in Florida, the company maintained stable overall financial performance, highlighting operational strength.
  • 7The Health Care Benefits segment showed robust revenue growth of 10.9% for the quarter, benefiting from increased premium revenues and favorable medical cost trends.

Frequently Asked Questions

The primary driver of revenue growth in the second quarter of 2022 was an 11.0% increase in total revenues to $80.6 billion. This growth was broad-based across all segments, with significant contributions from the 'Products' and 'Premiums' categories.

Profitability showed improvement, with net income attributable to CVS Health increasing by 6.0% for the quarter to $2.95 billion, resulting in diluted EPS of $2.23. For the first six months, net income rose by 5.1% to $5.26 billion, with diluted EPS of $3.97. Operating income also increased by 5.6% for the quarter.

The divestiture of PayFlex on June 1, 2022, resulted in a pre-tax gain of $225 million, which was recognized in the second quarter. This gain positively contributed to the operating income, particularly within the Health Care Benefits segment.

CVS Health continued to return capital to shareholders through share repurchases and dividends. In the first six months of 2022, the company repurchased approximately $2.0 billion of its common stock under its authorized repurchase program, and it also maintained its quarterly dividend payments.

Investors should be aware of the ongoing legal and regulatory landscape. Notably, the company entered into a $484 million settlement with the State of Florida to resolve opioid-related claims. The company also faces various other legal proceedings and investigations related to its PBM practices, prescription processing, and other business operations, though it states that these are not expected to have a material adverse effect on its financial position, reserves are in place for known contingencies, and it is defending its positions.